From RTTNews.:

Moderna, Inc. reported achieving 2023 COVID-19 vaccine sales of approximately $6.7 billion, including $6.1 billion of COVID-19 vaccine sales and recognition of $0.6 billion of deferred revenue related to the efforts with GAVI, The Vaccine Alliance. The company’s cash, cash equivalents, and investments at year-end 2023 were in excess of $13 billion.

The company anticipates the COVID-19 franchise to be profitable in 2024 and beyond, projecting approximately $4 billion in product sales for 2024, primarily due to COVID-19 vaccine sales and the launch of the RSV vaccine. Moderna expects to return to organic sales growth in 2025 and break even in 2026.

CEO Stephane Bancel stated that the company is preparing for the launch of Moderna’s second product, the RSV vaccine, and anticipates multiple milestones across their nine late-stage programs in 2024. The company is focused on returning to sales growth in 2025 through these product launches.

For more health news, visit rttnews.com. For comments and feedback, contact [email protected].



Read more: Moderna Sees COVID-19 Franchise To Be Profitable In Anticipated Sales Scenarios For 2024 And Beyond